Joshua Jennings
Stock Analyst at TD Cowen
(3.21)
# 963
Out of 4,829 analysts
68
Total ratings
42.86%
Success rate
2.87%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVR Anteris Technologies Global | Initiates: Buy | $15 | $4.21 | +256.29% | 1 | Jan 7, 2025 | |
| PODD Insulet | Maintains: Buy | $264 → $324 | $310.67 | +4.29% | 1 | Jan 3, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $100 → $110 | $102.86 | +6.94% | 7 | Dec 12, 2024 | |
| CBLL CeriBell | Maintains: Buy | $31 → $36 | $15.97 | +125.42% | 2 | Dec 9, 2024 | |
| TMDX TransMedics Group | Maintains: Buy | $175 → $120 | $111.50 | +7.62% | 9 | Nov 18, 2024 | |
| HUMA Humacyte | Reiterates: Buy | $10 | $1.19 | +740.34% | 2 | Oct 18, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $50 | $2.38 | +2,000.84% | 1 | Oct 2, 2024 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $75 → $99 | $53.11 | +86.41% | 3 | Sep 16, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Hold | $143 → $119 | $95.21 | +24.99% | 1 | Sep 6, 2024 | |
| VCEL Vericel | Maintains: Buy | $55 → $60 | $41.72 | +43.82% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $82.41 | -2.92% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $15.08 | +198.41% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $100 → $70 | $73.68 | -4.99% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $185 | $154.22 | +19.96% | 1 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $30.90 | +29.45% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $380.92 | +5.01% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $33.92 | +76.89% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $22.98 | +47.95% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $4.63 | +288.77% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $84.67 | +47.63% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $17.46 | +43.18% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $133.24 | -2.43% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $2.13 | +134.74% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $83.48 | +40.15% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $450 | $8.62 | +5,120.42% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $12.21 | -1.72% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $167.22 | +64.45% | 1 | Feb 7, 2020 |
Anteris Technologies Global
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $4.21
Upside: +256.29%
Insulet
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $310.67
Upside: +4.29%
Boston Scientific
Dec 12, 2024
Maintains: Buy
Price Target: $100 → $110
Current: $102.86
Upside: +6.94%
CeriBell
Dec 9, 2024
Maintains: Buy
Price Target: $31 → $36
Current: $15.97
Upside: +125.42%
TransMedics Group
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $111.50
Upside: +7.62%
Humacyte
Oct 18, 2024
Reiterates: Buy
Price Target: $10
Current: $1.19
Upside: +740.34%
Allurion Technologies
Oct 2, 2024
Initiates: Buy
Price Target: $50
Current: $2.38
Upside: +2,000.84%
PROCEPT BioRobotics
Sep 16, 2024
Maintains: Buy
Price Target: $75 → $99
Current: $53.11
Upside: +86.41%
Zimmer Biomet Holdings
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $95.21
Upside: +24.99%
Vericel
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $41.72
Upside: +43.82%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $82.41
Upside: -2.92%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $15.08
Upside: +198.41%
Jul 25, 2024
Downgrades: Hold
Price Target: $100 → $70
Current: $73.68
Upside: -4.99%
Jul 18, 2024
Maintains: Buy
Price Target: $195 → $185
Current: $154.22
Upside: +19.96%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $30.90
Upside: +29.45%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $380.92
Upside: +5.01%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $33.92
Upside: +76.89%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $22.98
Upside: +47.95%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $4.63
Upside: +288.77%
Feb 10, 2023
Maintains: Outperform
Price Target: $114 → $125
Current: $84.67
Upside: +47.63%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $17.46
Upside: +43.18%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $133.24
Upside: -2.43%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $2.13
Upside: +134.74%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $83.48
Upside: +40.15%
Dec 7, 2021
Initiates: Outperform
Price Target: $450
Current: $8.62
Upside: +5,120.42%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $12.21
Upside: -1.72%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $167.22
Upside: +64.45%